Home › Cholesterol › NCT06451770
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
Who can join
Ages 18 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol
About the study
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
What is being tested
- VERVE-201 (drug)
Sponsor: Verve Therapeutics, Inc. · Participants: 36 · Started: Oct 30, 2024
Contact the study team
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 317-615-4559
Official record on ClinicalTrials.gov — NCT06451770
Locations in the U.S.
| Florida | Clinical Study Center, Clearwater Clinical Study Center, Miami Lakes Clinical Study Center, Port Orange |
| New York | Clinical Study Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.